Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / S•• D•••••••••

A••••• acquires S•• D••••••••• from the State of Denmark in privatization process

Platform acquisitionannouncedannounced Mar 30, 2016Fact
What happened
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
unknown
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • A••••• E••••• P••••••• F••• I• (“A•••••”) has agreed with the State of Denmark to acquire S•• D•••••••••, a leading developer and producer of in vitro diagnostic products, mainly within clinical microbiology.
  • A•••••, a private equity firm focused on the Nordic market with offices in Stockholm and Copenhagen, counts healthcare including life sciences and diagnostics as one of its core focus areas.
Side not stated
  • – We believe that the A••••• team's know-how and experience within healthcare in general and life sciences and biotechnology in particular, coupled with our strong Danish presence, makes us very well positioned to support the growth and internationalisation of S•• D•••••••••, says R••••• M•••••••, r
  • A••••• acquires S•• D••••••••• from the State of Denmark in privatization process
Evidence
A••••• acquires S•• D••••••••• from the State of Denmark in privatization process
A••••• acquires S•• D••••••••• from the State of Denmark in privatization process | Private Equity Intelligence | DFX